IDT Receives Share of $3M in Biomedical Funding

Senator Harkin Announces over $3 Million for Biomedical Research in Iowa

WASHINGTON, D.C. – Senator Tom Harkin (D-IA) announced a total of $3,113,713 in National Institute of Health (NIH) funding for University of Iowa, Iowa State University and Integrated DNA Technologies, Inc. to conduct biomedical research. The funding was secured through the American Recovery and Reinvestment Act (ARRA), the economic recovery package. Harkin chairs the Appropriations subcommittee that funds National Institutes of Health (NIH) research and was able to secure $10.4 billion for medical research across the United States in the ARRA.

“I congratulate the recipients of these awards for being awarded this funding which will make biomedical research possible,” said Harkin. “I know these institutions will continue to do great research made possible through this money.”

These grants were awarded through the NIH, which funds biomedical research and research training at more than 3,000 institutions in the 50 states and territories.

Details of the grants are below.

· Integrated DNA Technologies, Inc. (based in Coralville) - $99,750 for research on Gene Silencing with U1 Adaptor Oligonucleotides.

· University of Iowa- $270,950 for research on Dosimetry Guided Phase II of 90Y-DOTA-tyr3-Octreotide + Retinoic Acid in Kids.

· University of Iowa- $305,502 for research on Chronic Alcohol and Pulmonary Immunity.

· University of Iowa- $651,120 for research on Chronic Ethanol, B Cell Competence and Lymphoid Integrity.

· University of Iowa- $371,938 for research on Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells.

· University of Iowa- $150,000 for the Center for Gene Therapy of Cystic Firbosis and Other Genetic Diseases.

· University of Iowa- $207,481 for research on Neurological Outcomes Among Pesticide Applicators.

· University of Iowa- $ 63,964 for Predoctoral Training in the Pharmacological Sciences.

· Iowa State University- $193,008 for research on Control of cap-independent translation by a viral 3' UTR.